Sarepta Therapeutics (SRPT) gives an update on Study 202.
At 96 weeks, DMD patients treated with eteplirsen "showed a continued stabilization of walking ability ... on the 6-minute walk test." (PR)
SRPT shares are off 3.6% premarket in what may be a "sell the news" event. Alternatively, investors could simply be experiencing a bit of SRPT fatigue following the 26% post-drisapersen data rally.